



# Highly immunogenic prime–boost DNA vaccination protects chickens against challenge with homologous and heterologous H5N1 virus



Anna Stachyra<sup>a</sup>, Anna Góra-Sochacka<sup>a</sup>, Róża Sawicka<sup>a</sup>, Katarzyna Florys<sup>b</sup>, Violetta Sączyńska<sup>b</sup>, Monika Olszewska<sup>c</sup>, Anna Pikuła<sup>c</sup>, Krzysztof Śmietanka<sup>c</sup>, Zenon Minta<sup>c</sup>, Bogusław Szewczyk<sup>d</sup>, Włodzimierz Zagórski<sup>a</sup>, Agnieszka Sirko<sup>a,\*</sup>

<sup>a</sup> Institute of Biochemistry and Biophysics, Polish Academy of Sciences, ul. Pawinskiego 5A, 02-106 Warsaw, Poland

<sup>b</sup> Institute of Biotechnology and Antibiotics, ul. Staroscinska 5, 02-516 Warsaw, Poland

<sup>c</sup> Department of Poultry Diseases, National Veterinary Research Institute, Al. Partyzantow 57, 24-100 Pulawy, Poland

<sup>d</sup> Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Kładki 24, 80-822 Gdansk, Poland

## ARTICLE INFO

### Article history:

Received 26 December 2013

Revised 17 February 2014

Accepted 17 February 2014

### Keywords:

Avian influenza

H5N1

Chicken

Poultry immunization

DNA vaccine

## ABSTRACT

Highly pathogenic avian influenza viruses (HPAIVs) cause huge economic losses in the poultry industry because of high mortality rate in infected flocks and trade restrictions. Protective antibodies, directed mainly against hemagglutinin (HA), are the primary means of protection against influenza outbreaks. A recombinant DNA vaccine based on the sequence of H5 HA from the H5N1/A/swan/Poland/305-135V08/2006 strain of HPAIV was prepared. Sequence manipulation included deletion of the proteolytic cleavage site to improve protein stability, codon usage optimization to improve translation and stability of RNA in host cells, and cloning into a commercially available vector to enable expression in animal cells. Naked plasmid DNA was complexed with a liposomal carrier and the immunization followed the prime–boost strategy. The immunogenic potential of the DNA vaccine was first proved in broilers in near-to-field conditions resembling a commercial farm. Next, the protective activity of the vaccine was confirmed in SPF layer-type chickens. Experimental infections (challenge experiments) indicated that 100% of vaccinated chickens were protected against H5N1 of the same clade and that 70% of them were protected against H5N1 influenza virus of a different clade. Moreover, the DNA vaccine significantly limited (or even eliminated) transmission of the virus to contact control chickens. Two intramuscular doses of DNA vaccine encoding H5 HA induced a strong protective response in immunized chicken. The effective protection lasted for a minimum 8 weeks after the second dose of the vaccine and was not limited to the homologous H5N1 virus. In addition, the vaccine reduced shedding of the virus.

© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/3.0/>).

## Introduction

DNA vaccines are new-generation vaccines offering many advantages over conventional ones [13]. They are relatively simple, easy and fast to produce, generate low costs in storage and transport, and are more stable than protein formulations. Numerous data show the effectiveness of experimental DNA immunizations against various viral, bacterial, parasitic and cancer diseases. However, only a few veterinary products have been registered to date in the USA and Canada, and despite several clinical trials, no human DNA vaccine is available [6,10]. Various experimental DNA vaccines have been tested in poultry [15]. The high potential of DNA immunization, particularly in cases requiring a rapid

response to an influenza pandemic have led to the development of this technology and increase of report on DNA vaccines for chickens against influenza [4,8,9,11,12,17,19,23].

The influenza virion has several structural and non-structural antigens, namely hemagglutinin (HA), neuraminidase (NA), capsid protein (M1), ion channel protein (M2), nucleoprotein (NP) and the components of the viral polymerase PA, PB1 and PB2 [22]. Although detectable antibody responses are observed against many viral proteins, the major determinants for a protective response are antibodies produced against surface glycoprotein HA, the most prominent antigen of the virus (see the review [20] and references therein). HA is synthesized as a precursor polypeptide H0 and is then cleaved into subunits H1 and H2. The HA cleavage site is the main determinant of the pathogenicity of influenza viruses. In low-pathogenic avian influenza viruses (LPAIVs) the cleavage site can be limited to a single arginine residue recognized

\* Corresponding author. Tel.: +48 226584801; fax: +48 226584804.

E-mail address: [asirko@ibb.waw.pl](mailto:asirko@ibb.waw.pl) (A. Sirko).

by extracellular trypsin-like proteases, while in high-pathogenic viruses (HPAIV) the H0 precursor contains a sequence that can be recognized by proteases present in nearly all cell types, which facilitates systemic spread of the virus [20,22].

In the EU, permission to vaccinate poultry against H5N1 HPAI can be granted after the fulfillment of strict requirements laid down in the EU Directive for the Control of AI (Council Directive 2005/94/EC). The directive is concerned with the high risk of a “silent spread” of the virus due to incomplete protection at a flock level, leading to the impossibility of differentiating the infected from the vaccinated individuals in case of usage of inactivated vaccines. Therefore, considering the needs of the DIVA (Differentiating Infected from Vaccinated Animals) strategy, there is a great demand for new-generation vaccines [2,5,18]. It is strongly recommended by the OIE and the EU that preventive and emergency vaccination should be an additional method of controlling and fighting the virus in case of disease outbreak, by protecting valuable flocks and reducing the spread of virus in restriction and buffer zones.

The H5N1 strain of HPAIV which is the object of our studies and caused the Asian epidemic in 2003 was first identified in domestic geese in China in 1996 [27]. After several years of spreading and genetic diverging in South Eastern Asia, some strains have crossed the Russian border and reached the Middle East and Europe [3]. Several local outbreaks appeared in almost all European countries, both on poultry farms and among wild birds. In March 2006, the first disease outbreak was reported in Poland in mute swans [14,25]. Despite the high standards of food and animal trade in the EU due to the intense human and animal movement the risk of virus re-emergence is high. In this study the immunization experiments were conducted with common broiler type chicken grown in a biologically secure poultry-house. The duration of the immunization experiments was 6 weeks, because such is the length of broilers' life. Two intramuscular doses of DNA vaccine were sufficient to stimulate the anti-HA response in sera of immunized chickens. The second series of experiments involved challenge with HPAI H5N1 viruses and were conducted in a P3 laboratory using SPF chickens of laying type, which allowed the time of the experiments to be extended to 8–13 weeks in order to test for the long-term protection. The challenge experiments indicated a high protective potential of the tested DNA vaccine. The immunized SPF chickens were protected in 100% against H5N1 virus from a homologous clade (clade 2.2) and in 80% against the H5N1 virus from a heterologous clade (clade 1).

## Materials and methods

### Plasmids and vaccine design

Based on the predicted amino acid sequence of HA from H5N1 A/swan/Poland/305-135V08/2006 strain of HPAIV (EpiFluDatabase [<http://platform.gisaid.org>]; Accession No. EPI156789), a synthetic gene optimized to the domestic chicken codon bias and containing deletion of the proteolytic cleavage site (from Arg-341 to Arg-346) was designed (GenBank Accession No. KC172926). Two variants of the DNA vaccine were prepared: (i) long, codon-optimized HA (aa 1–568) with the original N-terminal signal peptide of 16 amino acids (aa 1–16) and a deletion of the proteolytic cleavage site RRRKKR ( $\Delta$ 341–346) and (ii) short, codon-optimized HA, containing only aa 17–340 (only H1 subunit, without signal peptide). The non-optimal codons in the native HA gene sequence were replaced by codons optimized to chicken codon usage and the sequence was also checked for the absence of cryptic splice sites (commercial service by GenScript USA Inc.). The inserts were cloned into the pCI (Promega) between immediate-early enhancer/promoter from Cytomegalovirus (CMV) and a terminator/

polyadenylation signal from SV40. Plasmid DNA was purified using NoEndo JETSTAR Plasmid Kit (Genomed, Germany) and suspended in PBS pH 7.4, and the appropriate amount of DNA (62–250  $\mu$ g) was mixed with the Lipofectin transfection reagent (Life Technologies, USA) as recommended by the manufacturer. In each trial the same ratio of DNA amount (w):Lipofectin (v), 6:1 was used. The volume of one dose of vaccine was 160  $\mu$ l.

### Influenza viruses and stock preparation

Table 1 lists the used influenza viruses. The HPAIVs were propagated in the allantoic cavities of embryonated chicken eggs (Valo-Biomedica, Germany) in biosafety level 3 conditions of the National Veterinary Research Institute (Pulawy, Poland) and stored in aliquots at  $-70^{\circ}\text{C}$  (for challenge purpose) or inactivated with 0.1% formaldehyde (Sigma–Aldrich, MO, USA) for 2 h at  $37^{\circ}\text{C}$  (for hemagglutination inhibition test). The LPAIVs were either purchased or kindly provided by others. The viral stocks stored at  $-70^{\circ}\text{C}$  were titrated before use.

### Immunization and challenge experiments

Broilers (Ross 308) were housed in poultry-house in cages, in standard commercial conditions including temperature, photoperiod, litter and fodder. Five independent immunizations of broilers were conducted. Depending on the experiment, animals (7–15 per group) were immunized subcutaneously in the neck or intramuscularly in the breast muscle with the indicated amount of DNA complexed with Lipofectin. Blood was collected from the wing veins, allowed to coagulate, and centrifuged. The collected sera were kept at  $-20^{\circ}\text{C}$ .

Specific pathogen free (SPF) White Leghorn chickens, housed in a biosafety level 3 containment of the National Veterinary Research Institute, Pulawy, were immunized intramuscularly twice (using 1-ml syringe with  $0.5 \times 1.6$  mm needle) with the DNA vaccine containing 125  $\mu$ g of plasmid DNA complexed with Lipofectin. Prior to the challenge, the chickens were placed in separate isolators (Montair Andersen B.V., Holland) equipped with HEPA filters. Three challenge experiments were performed. The immunized chickens (10 birds/group in Experiments 1 and 3, and 5 birds in Experiment 2) as well as control (untreated, fully susceptible chickens, 2–5/group) were inoculated oculonasally with  $10^6$  50% egg infectious dose ( $\text{EID}_{50}$ ) of the respective virus in the volume of 100  $\mu$ l (50  $\mu$ l into the nares and 50  $\mu$ l into the eye per bird). Approximately 24 h after inoculation, 6-week-old contact SPF chickens (1 or 2 per group) were placed in the same isolators as the vaccinated chickens to monitor virus transmission. Other details are shown in Table 2.

### Ethic statements

The experiments were approved by the Second Local Ethical Committee for Animal Experiments at the Medical University of Warsaw, Permit Number 17/2009 (broilers) or the Second Local Ethical Committee for Animal Experiments at the University of Life Sciences in Lublin, Permit No. 26/2012 (SPF chickens). All efforts were made to minimize suffering. The chickens were monitored twice a day (morning and afternoon), including weekends. The immunized chickens were sacrificed (humanely euthanized by decapitation) about 3 weeks after the final immunization (about 6 weeks after hatching).

### ELISA

The 96-well polystyrene plates (Nunc, Denmark) were coated overnight at  $4^{\circ}\text{C}$  with 300 ng of HA antigen (A/swan/Poland/

**Table 1**  
Influenza viruses used in this study.

Experiment	Antigen	Clade	Source
DNA vaccine	H5N1 A/swan/Poland/305-135V08/2006	Clade 2.2	Department of Poultry Diseases, National Veterinary Research Institute, Pulawy, Poland
HI tests in Trials 1–5 (broilers)	H5N2 A/chicken/Belgium/150/1999	–	GD Deventer, Netherlands
Challenge Experiments 1 and 2	H5N1 A/turkey/Poland/35/07	Clade 2.2	Department of Poultry Diseases, National Veterinary Research Institute, Pulawy, Poland
Challenge Experiment 3	H5N1 A/crested eagle/Belgium/01/2004	Clade 1	Dr. T. van den Berg (CODA-CERVA, Brussels, Belgium)
HI tests in Experiments 1–3 (SPF chickens)	H5N1 A/Ck/Scotland/59 Inactivated Antigen (Sc)	Eurasian group	Animal Health and Veterinary Laboratories Agency, Waybridge, UK
	H5N1 A/turkey/Poland/35/07(Po)	Clade 2.2	Department of Poultry Diseases, National Veterinary Research Institute, Pulawy, Poland
	H5N1 A/crested eagle/Belgium/01/2004(Be)	Clade 1	Dr. T. van den Berg (CODA-CERVA, Brussels, Belgium)

**Table 2**  
Design of immunization and challenge experiments.

Experiment/route		Group size			Respective treatment day after hatching		
		Imm	Cntr	Cnct	Prime/boost	Blood	Challenge
Immunization (broilers)	Trial 1/sc	14	10	n/a	10/22	21/42	n/a
	Trial 2/sc	28	14	n/a	5/19	18/40	n/a
	Trial 3/sc, im	30	10	n/a	6/21	20/42	n/a
	Trial 4/im	24	5	n/a	7/21	20/38	n/a
	Trial 5/im	24	3	n/a	7/21	20/42	n/a
Challenge (SPF)	Exp 1/im	10	3	2	7/21	21/35/42/56	42
	Exp 2/im	5	2	1	7/21	21/35/42/63/ 70/77	77
	Exp 3/im	10	5	2	7/21	21/35/42/56	42

Routes of immunization (sc – subcutaneous; im – intramuscular). Imm – immunized; Cntr – control (non-immunized); Cnct – contact; prime – first immunization; boost – second immunization; blood – blood collection; challenge – experimental infection with H5N1 virus; n/a – non-applicable. For all experiments with experimental infection (challenge) SPF (specific pathogen free) chickens were used.

305–135V08/2006 (H5N1)) produced in a baculovirus system (Oxford Expression Technologies, UK). Bound IgY were detected using goat anti-chicken IgY (Fc-specific)-HRP (Pierce/Thermo Scientific, IL, USA) antibodies. Results were analyzed using the STATISTICA program (StatSoft, Poland).

### Hemagglutinin Inhibition

The HI test was conducted according to the standard procedure [1]. Shortly, the collected sera (25 µl of sera in serial twofold dilutions) were incubated for 25 min in a titration plate with four HA units of the inactivated antigen. Next, a suspension of 1% hen erythrocytes was added and incubated for 30 min. The HI titer was determined as the reciprocal of the highest dilution in which hemagglutination was inhibited. Sera from Trials 1 to 5 were tested using the heterologous strain H5N2 A/chicken/Belgium/150/1999 (GD Deventer, Netherlands). Sera from the Challenge Experiments 1–3 were tested with a much broader range of antigens (see Table 1).

### Determination of viral titers

The level of viral RNA in samples from challenged chickens was assayed by quantitative real time RT-PCR/M using RNA isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany) as described [21]. Oligonucleotides M-25 (5'-AGATGAGTCTTCTAA CCGAGGTCG-3') and M-124 (5'-TGC AAAAACATC TTCAAGTCTCT-3') were used as primers and M-64 (5'-FAM-TCAGGCCCTC AAAGCCGA-TAMRA-3') served as a probe. Quantitative standards of RNA extracted from 10-fold dilutions of a titrated virus homologous to the challenge

strain were used to convert and express the QRT-PCR Ct values as equivalent EID<sub>50</sub> (eqEID<sub>50</sub>) per milliliter of swab fluid from oropharyngea and cloaca.

## Results

### Immune responses of chickens to DNA vaccines


Five independent immunization experiments with slightly different time schedule of priming, boosting and blood collection were conducted in experimental farm conditions (Table 2, Fig. 1). The duration of each experiment did not exceed 6 weeks, the life span of broilers. In the initial experiment (Trial 1) we focused on the evaluation of the immunogenic potential of two variants (short and long) of the DNA vaccine. The plasmid containing the long sequence appeared to be better vaccine candidate than the one with the short (H1) sequence (Fig. 1A), therefore we concentrated only on the long DNA vaccine in further experiments. The minimal amount of plasmid DNA inducing satisfactory response by subcutaneous route was assessed in the next experiment (Trial 2) as 125 µg (Fig. 1B). When two high doses of 250 µg DNA were administered without Lipofectin the anti-HA response was significantly lower than the response to two doses of 250 µg or two doses of 125 µg administered with the carrier.

Subsequent trials (Trials 3–5) (i) allowed us to choose the intramuscular route as superior to the subcutaneous, (ii) confirmed that the intramuscularly injected dose of 125 µg of the long variant of the DNA vaccine is sufficient to induce anti-HA humoral response in 100% of chicken, and (iii) demonstrated that two doses of the vaccine are necessary to induce antibodies capable of


hemagglutination inhibition (Fig. 1C). The results of all trials consistently indicated that two weeks after priming (just before boosting) anti-HA antibodies could be detected in sera. However, the second dose of the vaccine (boosting) resulted in a strong increase of anti-HA antibody titers in most groups (as detected 3 weeks after the boost) and in increase of hemagglutinin inhibition (HI) activity (Fig. 1 and Supplementary Fig. 1). Generally, irrespective of the experimental group, no HI activity was detected in sera with low titers of anti-HA antibodies.

#### Dynamics of serological response

The previously optimized immunization schedule (intramuscular route, 125- $\mu$ g dose, prime/boost on days 7/21) was applied to SPF chickens. Then, on day 42 (Experiment 1 and 3) or 77 (Experiment 2) chickens were challenged with either H5N1 HPAIV from clade 2.2 (Experiments 1–2) or H5N1 HPAIV from clade 1 (Experiment 3). The HI response in sera of immunized and challenged chickens is shown in Fig. 2 and Supplementary Fig. 2. Consistently, the best HI



**Fig. 1.** Chicken immune responses to DNA vaccine. Anti-HA Ab measured by ELISA (A–C) and HI of corresponding sera (C) are shown for individual chickens in each group. The number (*n*) of chicken per group is indicated; sc, subcutaneous; im, intramuscular; buffer – chickens received two doses of buffer; vector – chickens received empty vector; (-)carrier – chickens received DNA without lipid carrier; doses of DNA (250, 125 or 62  $\mu$ g) are specified; chickens were immunized twice unless indicated otherwise, where 1 $\times$  denotes the group which received only the first dose. In Trial 1 (A) either the short or long variant of the vaccine was used, while in Trials 2 (B) and Trials 3–5 (C) only the long variant was used.




**Fig. 2.** Dynamics of HI titer in immunized and infected groups of chickens. Chickens in Experiments 1 and 2 were challenged with H5N1 from clade 2.2 (homologous to the vaccine), while in Experiment 3 with H5N1 from heterologous clade 1. Challenge was on day 42 in Experiments 1 and 3 and on day 77 in Experiment 2. Chickens from the control (non-immunized) groups had no detectable serological response to any of the antigens tested and they are not shown. Annotations on horizontal axes refer to the type of virus used for HI test (Sc – A/Ck/Scot/59; Po – A/turkey/Poland/35/07; Be – A/crested eagle/Belgium/01/2004) and to the day of blood collection.

response was against an antigen homologous to the one encoded by the DNA vaccine. At 3 weeks post booster (wpb) (challenge day in Experiment 1 and Experiment 3) all birds were HI-positive with the following values of Geometric Mean Titers (GMT): 169 (Experiment 1), 97 (Experiment 2) and 111 (Experiment 3). However, only 60–80% of birds tested on the challenge day (3 wpb or 8 wpb) were found positive with antigen from heterologous and antigenically distant clade and the percentage of seropositive chickens never reached 100%. The strong elevation of HI antibody was always observed 2 weeks after challenge.

#### Protection against challenge and viral shedding

The survival ratio after the challenge is shown in Fig. 3, while the amount of viral RNA in swabs collected from the immunized/infected and the contact groups is summarized in Table 3. All control chickens (non-immunized, challenged) died by 3 dpi and large amounts of the virus (usually  $>5 \log_{10}$  EID<sub>50</sub> per ml swab fluid) were found. In Experiment 1 (challenge with the homologous virus 3 weeks after the boosting), no clinical signs or mortality were observed in immunized chickens or contact birds (Fig. 3A). The small amount of the virus (up to  $3 \log_{10}$  EID<sub>50</sub>) was detected in oropharyngeal swabs of single birds tested at 3 dpi and 14 dpi. This seems, however, to be probably below the infecting dose, which is reflected in the survival of the contact birds. In Experiment 2 (challenge with the homologous virus 8 weeks after boosting), the vaccinated and challenged chickens remained clinically healthy, but the contact bird developed clinical symptoms and died 7 days after the vaccinated birds had been challenged (Fig. 3B). The virus was found at 3 dpi in the oropharyngeal swabs collected from 2 immunized birds (amount of RNA equivalent to  $3.3 \log_{10}$  EID<sub>50</sub>) while in dead contact chicken a viral RNA was present both in respiratory and digestive tracts (quantity corresponding to 6.2 and  $4.6 \log_{10}$  EID<sub>50</sub>, respectively). Regarding Experiment 3 (challenge with the virus from the heterologous clade 3 weeks after boosting), three immunized and infected birds died on days 5, 10 and 13, but viral RNA was never detected in swabs taken from the immunized chicken found dead at 13 dpi. Both contact chickens were found dead 2 days after they had been placed in the isolator with the challenged birds (Fig. 3C). The vaccinated and challenged chickens shed the virus up to 10 dpi with the peak at 3 dpi (seven birds, amount of RNA equivalent to  $2.4$ – $5.8 \log_{10}$  EID<sub>50</sub>, see Table 3).



**Fig. 3.** Results of challenge experiments. (A) Experiment 1 – infection with homologous HPAIV three weeks post boost (wpb). (B) Experiment 2 – infection with homologous HPAIV 8 wpb. (C) Experiment 3 – infection with heterologous HPAIV 3 wpb. The data are shown as percentage survival in respective groups (c – control chickens, cc – contact chickens, ic – immunized chickens).

#### Discussion

This work focused on testing the DNA vaccine effective in chickens that can be used in case of influenza outbreak. Comparison of two immunization routes resulted in choosing the intramuscular injection as better and more reliable than the subcutaneous one (Fig. 1C). This route of injection was also more convenient for the personnel and, in our evaluation, better tolerated by birds. In other reports this route was also often used for DNA immunizations with HA-encoding plasmids [7,8,12,16] and gave good results; however, other, more sophisticated methods like gene gun [9], electroporation [19] or needle free jet injector [17] were sometimes found more effective. We have also established the minimal dose inducing the satisfactory response as 125  $\mu$ g. In other works a very broad range of doses was tested and showed to be effective. Usually around 10–200  $\mu$ g ensured high or average level of response and protection [7,8,9,12,16,17,19].

The reported here immunization protocol, initially optimized in broilers in experimental farm conditions, was used in three challenge experiments with H5N1 HPAIVs using SPF White Leghorn chickens kept in a biosafety level 3 laboratory. Two HPAIV strains were used for challenge. The first was A/turkey/Poland/35/07 from



**Table 3**  
Viral RNA detection after challenging of vaccinated chickens.

		Days post infection (d.p.i.)							
		3		7		10		14	
		O	C	O	C	O	C	O	C
		(+/t)	(+/t)	(+/t)	(+/t)	(+/t)	(+/t)	(+/t)	(+/t)
Exp 1	Immun	1/10 (3log <sub>10</sub> EID <sub>50</sub> )	0/10	0/10	0/10	0/10	0/10	1/10 (<2log <sub>10</sub> EID <sub>50</sub> )	0/10
	Contact	0/2	0/2	0/2	0/2	0/2	0/2	0/2	0/2
Exp 2	Immun	2/5 (<2–3.3log <sub>10</sub> EID <sub>50</sub> )	0/5	0/5	0/5	0/5	0/5	0/5	0/5
	Contact	0/1	0/1	1/1 (6.2log <sub>10</sub> EID <sub>50</sub> )	1/1 (4.6log <sub>10</sub> EID <sub>50</sub> )	– <sup>a</sup>	–	–	–
Exp 3	Immun	7/10 (2.4–5.8log <sub>10</sub> EID <sub>50</sub> )	0/10	3/9 <sup>b</sup> (3.0–5.3log <sub>10</sub> EID <sub>50</sub> )	1/9 (3.3log <sub>10</sub> EID <sub>50</sub> )	0/9	1/9 (<2log <sub>10</sub> EID <sub>50</sub> )	0/7 <sup>c</sup>	0/7
	Contact	2/2 (5.3–6.9log <sub>10</sub> EID <sub>50</sub> )	2/2 (6.1–7.0log <sub>10</sub> EID <sub>50</sub> )	– <sup>d</sup>	–	–	–	–	–

Results are shown for immunized (Immun) and contact chickens. Results for corresponding control groups (non-immunized and infected) are not shown. These chickens always died by 3 dpi and had large amounts of the virus (usually >5 log<sub>10</sub> EID<sub>50</sub> per ml of swab). The number of virus-positive (+) and of all individuals (total, t) in each group is provided. The amount of viral RNA in shedding chickens is shown in brackets. O – oropharyngeal swabs, C – cloacal swabs.

Experimental infection (challenge) was performed on 42nd (Exp 1 and Exp 3) and on 77th day after hatching (Exp 2) with either virus from the homologous clade (Exp 1 and Exp 2) or virus from a heterologous clade (Exp 3). Results obtained with the H5N1 virus from the clade homologous to the one used for preparing the DNA vaccine are highlighted.

<sup>a</sup> Bird died on 7 dpi.

<sup>b</sup> Bird died on 5 dpi.

<sup>c</sup> One bird died on 10 dpi and one bird died on 13 dpi.

<sup>d</sup> Birds died on 3 and 4 dpi.

clade 2.2 that reached Europe at the end of the year 2005 and circulated for several months in European countries causing small local outbreaks. The second was A/crested eagle/Belgium/01/04 from the distinct clade 1 which was circulating in southern Asia for several years and was once found at the Brussels airport in smuggled birds [26]. The mortality rate of the challenged animals was monitored, virus shedding and transmission were tested, and the dynamics of serological response (HI test) followed. All immunized birds were protected against the homologous virus used in challenge Experiments 1 and 2. Transmission of the virus was absent in the challenge Experiment 1 (infection at 3 wpb), while it was observed in Experiment 2 (infection at 8 wpb). As a result, a control contact chicken died 7 days after inoculation. It should be pointed out that shedding of the virus was mild and infection in the contact chicken developed with a delay of several days. Of the ten chickens vaccinated in Experiment 3 (challenge with heterologous H5N1 HPAIV) two died and had moderate to high levels of viral RNA in oropharyngeal and cloacal swabs, as well as in the lung, brain, kidney and spleen samples. The third chicken died also at the last day of observation. However, it was clinically healthy throughout the experiment and no virus RNA was detected at any time; therefore, we assumed that the reason of its death could be other than viral infection. The two contact chickens also died, proving transmission of the virus from vaccinated chickens. However, in order to get statistically significant results concerning virus transmission from the vaccinated to not-vaccinated birds it would be necessary to use a larger group of contact birds.

The H5N1 virus is highly variable and the existence of multiple antigenic and genetic variants makes the generation of a universal vaccine difficult or even impossible. A partial solution to the problem may be a “multi-clade” DNA vaccine which should potentially protect against a broader spectrum of viruses [28]. Vaccination against avian influenza is one of the tools in the control of the disease and generation of a vaccine that elicits even partial protection can greatly help limit the spread of infections in susceptible populations. The reported DNA vaccine provides 100% and 70% protection against, respectively, a homologous and heterologous virus and fulfills the criteria established by the World Organization for

Animal Health for an efficient AI vaccine [24]. The major advantage of this vaccine is that it can be used as a part of a DIVA strategy since the antibodies are produced exclusively against viral hemagglutinin. Although it still needs to be optimized in order to reduce its cost, optimize the immunization schedule and/or administration route, we believe that the similar DNA vaccines can be used in future as part of prophylactic, preventive or emergency strategies in the protection of valuable flocks against H5N1.

## Acknowledgements

We thank to Dr. Paweł Majewski (University of Warsaw) and Dr. Kazimierz Jaszcak (Institute of Genetics and Animal Breeding, PAS) for supplying hen erythrocytes. Anna Doraczyńska-Filipczak for excellent veterinary support during broiler immunization, Elżbieta Juszczak, Michał Jóźwiak and Krzysztof Wyrostek for invaluable support in challenge experiments. This work was supported by Innovative Economy Program, Grant No. WND-POIG.01.01.02-00-007/08 in frame of Vaccine Cluster Consortium (VCC): Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland (IBB); Institute of Biotechnology and Antibiotics, Warsaw, Poland (IBA); Department of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland (UG); Kucharczyk TE sp. z o.o., Warsaw, Poland (KTE); Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Tuwima 10, 10-747 Olsztyn, Poland (IAR); Department of Poultry Diseases, National Veterinary Research Institute, Pulawy, Poland (PIWet). The following members of the VCC are acknowledged for their valuable support: Jacek Bardski (IBB), Piotr Borowicz (IBA), Grażyna Płucienniczak (IBA), Krzysztof Kucharczyk (KTE), Jerzy Radecki (IAR), Hanna Radecka (IAR).

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.trivac.2014.02.002>.

## References

- [1] [O.I.E.] World Organization for Animal Health, Avian influenza, in: *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*, vol. 1, 2012, p. 2 (Chapter 2.3.4).
- [2] I. Capua, Vaccination for notifiable avian influenza in poultry, *Rev. Sci. Tech.* 26 (2007) 217–227.
- [3] G. Cattoli, A. Fusaro, I. Monne, I. Capua, H5N1 virus evolution in Europe – an updated overview, *Viruses* 1 (2009) 1351–1363.
- [4] Z. Chen, S. Kadowaki, Y. Hagiwara, T. Yoshikawa, T. Sata, T. Kurata, S. Tamura, Protection against influenza B virus infection by immunization with DNA vaccines, *Vaccine* 19 (2001) 1446–1455.
- [5] European Commission, Vaccination of poultry against Highly Pathogenic Avian Influenza H5N1 (DIVA strategy), Discussion paper, European commission SANCO/10103/2006 rev.2 (2006).
- [6] B. Ferraro, M.P. Morrow, N.A. Hutnick, T.H. Shin, C.E. Lucke, D.B. Weiner, Clinical applications of DNA vaccines: current progress, *Clin. Infect. Dis.* 53 (2011) 296–302.
- [7] B. Jalilian, A.R. Omar, M.H. Bejo, N.B. Alitheen, M. Rasoli, S. Matsumoto, Development of avian influenza virus H5 DNA vaccine and MDP-1 gene of *Mycobacterium bovis* as genetic adjuvant, *Genet. Vaccines Ther.* 8 (2010) 4.
- [8] Y. Jiang, K. Yu, H. Zhang, P. Zhang, C. Li, G. Tian, Y. Li, X. Wang, J. Ge, Z. Bu, H. Chen, Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector, *Antiviral Res.* 75 (2007) 234–241.
- [9] S. Kodihalli, D.L. Kobasa, R.G. Webster, Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines, *Vaccine* 18 (2000) 2592–2599.
- [10] M.A. Kutzler, D.B. Weiner, DNA vaccines: ready for prime time?, *Nat. Rev. Genet.* 9 (2008) 776–788.
- [11] C.W. Lee, D.A. Senne, D.L. Suarez, Development and application of reference antisera against 15 hemagglutinin subtypes of influenza virus by DNA vaccination of chickens, *Clin. Vaccine Immunol.* 13 (2006) 395–402.
- [12] K.L. Lim, S.D. Jazayeri, S.K. Yeap, N.B. Mohamed Alitheen, M.H. Bejo, A. Ideris, A.R. Omar, Co-administration of avian influenza virus H5 plasmid DNA with chicken IL-15 and IL-18 enhanced chickens immune responses, *BMC Vet. Res.* 8 (2012) 132.
- [13] M.A. Liu, DNA vaccines: an historical perspective and view to the future, *Immunol. Rev.* 239 (2011) 62–84.
- [14] Z. Minta, K. Śmietanka, K. Domańska-Blicharz, G. Tomczyk, T. Wijaszka, Highly pathogenic avian influenza H5N1 in wild birds in Poland analysis of first cases, *Medycyna Wet* 63 (2007) 1349–1352.
- [15] G.L. Oshop, S. Elankumaran, R.A. Heckert, DNA vaccination in the avian, *Vet. Immunol. Immunopathol.* 89 (2002) 1–12.
- [16] S. Oveissi, A.R. Omar, K. Yusoff, F. Jahanshahi, S.S. Hassan, DNA vaccine encoding avian influenza virus H5 and Esat-6 of *Mycobacterium tuberculosis* improved antibody responses against AIV in chickens, *Comp. Immunol. Microbiol. Infect. Dis.* 33 (2010) 491–503.
- [17] S. Rao, W.P. Kong, C.J. Wei, Z.Y. Yang, M. Nason, D. Styles, L.J. DeTolla, A. Panda, E.M. Sorrell, H. Song, H. Wan, G.C. Ramirez-Nieto, D. Perez, G.J. Nabel, Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice, *PLoS ONE* 3 (2008) e2432.
- [18] N.J. Savill, S.G. St Rose, M.J. Keeling, M.E. Woolhouse, Silent spread of H5N1 in vaccinated poultry, *Nature* 442 (2006) 757.
- [19] S. Shan, Y. Jiang, Z. Bu, T. Ellis, X. Zeng, J. Edwards, G. Tian, Y. Li, J. Ge, H. Chen, S. Fenwick, Strategies for improving the efficacy of a H6 subtype avian influenza DNA vaccine in chickens, *J. Virol. Methods* 173 (2011) 220–226.
- [20] J.J. Skehel, D.C. Wiley, Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin, *Annu. Rev. Biochem.* 69 (2000) 531–569.
- [21] E. Spackman, D.A. Senne, T.J. Myers, L.L. Bulaga, L.P. Garber, M.L. Perdue, K. Lohman, L.T. Daum, D.L. Suarez, Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes, *J. Clin. Microbiol.* 40 (2002) 3256–3260.
- [22] D.A. Steinhauer, J.J. Skehel, Genetics of influenza viruses, *Annu. Rev. Genet.* 36 (2002) 305–332.
- [23] D.L. Suarez, S. Schultz-Cherry, The effect of eukaryotic expression vectors and adjuvants on DNA vaccines in chickens using an avian influenza model, *Avian Dis.* 44 (2000) 861–868.
- [24] Swayne, D.E., *Avian influenza*, in: *OIE Terrestrial Manual*, 2012 (Chapter 2.3.4).
- [25] K. Śmietanka, Z. Minta, K. Domańska-Blicharz, G. Tomczyk, T. Wijaszka, Avian influenza H5N1 outbreak in a flock of mute swans in the city of Toruń, Poland in 2006, *Bull. Vet. Inst. Pulawy* 52 (2008) 491–495.
- [26] S. Van Borm, I. Thomas, G. Hanquet, B. Lambrecht, M. Boschmans, G. Dupont, M. Decaestecker, R. Snacken, T. van den Berg, Highly pathogenic H5N1 influenza virus in smuggled Thai eagles, Belgium, *Emerg. Infect. Dis.* 11 (2005) 702–705.
- [27] X. Xu, Subbarao, N.J. Cox, Y. Guo, Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong, *Virology* 261 (1999) 15–19.
- [28] F. Zhou, G. Wang, P. Buchy, Z. Cai, H. Chen, Z. Chen, G. Cheng, X.F. Wan, V. Deubel, P. Zhou, A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses, *J. Virol.* 86 (2012) 6970–6978.